Publications by authors named "Amy B Heimberger"

Are you Amy B Heimberger?   Register this Author


Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients.
J Neurooncol 2018 Jan 30;136(1):33-39. Epub 2017 Sep 30.
Department of Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Mailstop BCM305, Houston, TX, 77030, USA.


Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
Neuro Oncol 2017 Aug;19(8):1047-1057
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas; Caris Life Sciences, Phoenix, Arizona; Departments of Biostatistics, Neuro-Pathology, Neuro-Oncology, Pediatrics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.


Interrogating Metabolism in Brain Cancer.
Magn Reson Imaging Clin N Am 2016 Nov;24(4):687-703
Department of Cancer Systems Imaging, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA; The University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address:


PD-L1 expression and prognostic impact in glioblastoma.
Neuro Oncol 2016 Feb 30;18(2):195-205. Epub 2015 Aug 30.
Departments of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (E.K.N., J.W., N.K.Y., N.H., L.-Y.K., K.G., X.L., A.B.H.); Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (S.Z.); Center for RNA Interference and Non-Coding RNAs, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (C.I.); Flow Cytometry and Cell Imaging Core Facility, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.K.B.); Neuropathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (G.N.F.); Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (G.A.C.); Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (C.A.C.); Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (C.C., K.R.); Lion Biotechnologies, Woodland Hills, California (J.Q.C., L.R.); Dept. of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida (J.Q.C., L.R.).

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.
Cancer Res 2015 Sep;75(17):3505-18
Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas. The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas.

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Neuro Oncol 2015 Jun 13;17(6):854-61. Epub 2015 Jan 13.
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (J.S.); The Neurological Institute of Columbia University, New York, New York (R.K.L.); Stanford Cancer Center, Stanford, California (L.D.R.); Duke University Medical Center, Durham, North Carolina (D.A.R., G.E.A., D.D.B., J.H.S.); Evanston Northwestern Healthcare, Evanston, Illinois (N.A.P.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.D.G.); University of Washington School of Medicine, Seattle, Washington (M.M.M.); Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah (R.J.); Yale University School of Medicine, New Haven, Connecticut (J.M.B); University Hospital-Case Medical Center & Case Comprehensive Cancer Center, Cleveland, Ohio (A.S.); Scott Cruickshank & Associates, Inc., Santa Barbara, C alifornia (S.C.); Celldex Therapeutics, Inc., Hampton, New Jersey (J.A.G., T.K., T.A.D.); University of Texas M.D. Anderson Cancer Center, Houston, Texas (A.B.H.).

FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells.
Cancer Res 2015 Jun 1;75(11):2337-48. Epub 2015 Apr 1.
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas.

Epidermal growth factor receptor and variant III targeted immunotherapy.
Neuro Oncol 2014 Oct;16 Suppl 8:viii20-5
The Preston Robert Tisch Brain Tumor Center (K.L.C., P.C.G., C.M.S., J.H.S.); Division of Neurosurgery, Department of Surgery, Duke University Medical Center Durham, North Carolina (K.L.C., P.C.G., C.M.S., J.H.S.); Department of Biomedical Engineering, Duke University Durham, North Carolina (P.C.G.); Department of Pathology, Duke University Medical Center Durham, North Carolina (J.H.S.); Department of Immunology, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center Houston, Texas (H.G.C., L.J.N.C.); Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center Houston, Texas (A.B.H.).

Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.
Cancer Immunol Res 2014 Sep 17;2(9):867-77. Epub 2014 Jun 17.
Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida.

Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma.
J Natl Cancer Inst 2014 Aug 28;106(8). Epub 2014 Jun 28.
Affiliations of authors: Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China (SX, X-GL), Department of Neurosurgery (SX, JW, FW, L-YK, X-YL, EN, KG, TD, YY, FFL, GR, ABH), Department of Biostatistics (WQ), Department of Pathology (GNF), and Department of Experimental Therapeutics (GAC), University of Texas M. D. Anderson Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX (NKY); Texas A&M University College of Veterinary Medicine & Biomedical Sciences, College Station, TX (VF).


BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Cancer Immunol Immunother 2013 Jun 17;62(6):983-7. Epub 2013 Apr 17.
Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.


The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.
Int J Cancer 2012 Jul 24;131(1):8-17. Epub 2011 Aug 24.
Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA.


Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype.
Clin Cancer Res 2011 Jul 13;17(14):4642-9. Epub 2011 Apr 13.
Departments of Neurosurgery and Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.


Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.
Clin Cancer Res 2010 Dec 4;16(23):5722-33. Epub 2010 Oct 4.
Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.


Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.
Clin Cancer Res 2010 May 13;16(9):2550-61. Epub 2010 Apr 13.
Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA.




A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.
Cancer Immunol Immunother 2009 Jul 11;58(7):1023-32. Epub 2008 Nov 11.
Department of Neurosurgery, Unit 442, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA.









MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
Neuro Oncol 2016 05 11;18(5):639-48. Epub 2015 Dec 11.
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas (J.W., E.K.N., L.-Y.K., Y.H., S.X., K.G., X.L., N.H., A.B.H.); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas (W.Q., S.Z.); Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas (C.I.); Departments of Neuropathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (G.N.F.); Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (M.R.G.); Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (W.O.); Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas (G.A.C.); Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China (S.X.).


Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
J Immunother 2016 06;39(5):205-17
*Division of Pediatrics Departments of ‡Biostatistics ∥Neurosurgery §Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center †The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX.

miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis.
Cancer Res 2016 07 31;76(14):4293-304. Epub 2016 May 31.
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas.

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Neuro Oncol 2016 10 1;18(10):1357-66. Epub 2016 Jul 1.
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (S.T.G., Y.H., A.B.H.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (S.-P.W., J.d.G.); Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (R.G.W.V.); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (S.Z.); Department of Neuropathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (G.N.F.); Caris Life Sciences, Phoenix, Arizona, USA (J.X., Z.G., S.K.R., D.S.); The University of Sydney, Sydney, Australia (M.K.)



Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
Cancer Cell 2017 07;32(1):42-56.e6
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. Electronic address:


OF